Global peak left atrial longitudinal strain assessed by transthoracic echocardiography is a good predictor of left atrial appendage thrombus in patients in sinus rhythm with heart failure and very low ejection fraction – an observational study

Jacek Kurzawski¹, Agnieszka Janion-Sadowska¹, Łukasz Zandecki²*, Łukasz Piatek², Dorota Kozieli² and Marcin Sadowski²

Abstract

Background: Peak left atrial longitudinal strain (PALS) can help identify left atrial appendage thrombus (LAAT) in patients with atrial fibrillation. Nevertheless, few studies have been performed in patients in sinus rhythm without established indications for anticoagulation but with increased risk of LAAT, such as heart failure (HF) with severe left ventricular systolic dysfunction patients. The primary aim of this study was to identify clinical and transthoracic echocardiography predictors of LAAT in HF patients with very low left ventricular ejection fraction and sinus rhythm. The secondary objective was to analyze frequencies and predictors of a composite clinical endpoint of death or hospitalization for ischemic stroke.

Methods: We included 63 patients with HF, left ventricular ejection fraction < 25%, sinus rhythm at presentation, no history of atrial fibrillation, and without any established indications for anticoagulation. We determined whether clinical and transthoracic echocardiography parameters, including left atrial strain analysis, predicted LAAT. Transesophageal echocardiography was performed in all patients. When LAAT was detected, anticoagulation was recommended. The participants were followed for a median of 28.6 months (range 4–40) to determine the composite endpoint.

Results: LAAT was found in 20 (31.7%) patients. Global PALS was the best independent predictor of LAAT in univariate and multivariate logistic regression analyses (Gini coefficient 0.65, area under the receiver-operating characteristic curve 0.83). A global PALS value below 8% was a good discriminator of LAAT presence (odds ratio 30.4, 95% CI 7.2–128, p < 0.001). During follow-up, 18 subjects (28.6%) reached the composite clinical endpoint. CHA²DS²-VASc score, use of angiotensin-converting-enzyme inhibitors or angiotensin receptor blockers, and body surface area were significant predictors for the composite endpoint of death or hospitalization for ischemic stroke in the multivariate regression model.

(Continued on next page)
Conclusions: LAAT was relatively common in our group of HF patients and PALS has shown prognostic potential in LAAT identification. Further research is needed to determine whether initiation of anticoagulation or additional screening supported by PALS measurements will improve clinical outcomes in these patients.

Keywords: Peak left atrial longitudinal strain, Left atrial appendage thrombus, Heart failure with reduced ejection fraction, Sinus rhythm

Background
Heart failure (HF) with reduced left ventricular (LV) ejection fraction (LVEF) is associated with an increased risk of ischemic stroke and mortality, in both sinus rhythm (SR) and in atrial fibrillation (AF). The risk of stroke in HF patients appears to be directly related to the degree of LV systolic dysfunction and increases when the LVEF < 30% [1]. The risk may be even higher in subjects with extremely low LVEF values (< 15%) [2]. However, the overall stroke rate that may be associated with HF is too low to justify anticoagulation in all patients, even in those with reduced LVEF [3]. Despite limited evidence, the current opinion holds that anticoagulation should be considered in HF patients with reduced LVEF and previous thromboembolism or with newly diagnosed intracardiac thrombus [4].

Many imaging modalities are employed to detect intracardiac thrombi, each of which has limitations. Transesophageal echocardiography (TEE) is a semi-invasive procedure. Computed tomography entails substantial radiation exposure and potential nephrotoxicity due to intravenous contrast agents. Magnetic resonance is costlier and is not always readily available. By contrast, peak atrial longitudinal strain (PALS) alone is reported to be useful for functional analysis of the left atrium (LA) [5, 6] and in prediction of left atrial appendage thrombus (LAAT) or reduced LA appendage velocity in patients with AF [5, 7, 8]. There is insufficient data on PALS performance in patients with SR with an increased risk of LAAT, such as those with HF with severe LV systolic dysfunction. Two transthoracic echocardiography (TTE) techniques are currently used for functional analysis of LA: speckle tracking echocardiography and tissue doppler imaging (TDI). Both use standard two-dimensional images for the analysis of myocardial deformation and have some well-acknowledged advantages and disadvantages [9]. LA strain assessment techniques are fairly simple with high feasibility and reproducibility [8, 10]. In patients with SR, both PALS in the conduit phase and peak atrial contraction strain (PACS) analyses are feasible [11, 12]. Nevertheless, it is not known if PALS predicts LAAT in patients in SR.

The main objective of this study was to identify predictors of LAAT presence in patients with HF, very low EF and in SR. The additional objective was to analyze the clinical outcomes in these patients.

Methods
Study design
The study was conducted at Swietokrzyskie Cardiology Centre in a large tertiary hospital in Poland.

The primary aim of this study was to determine whether any clinical or TTE data, including PALS, are independent predictors of LAAT in patients with very low EF, with SR at presentation, without history of AF, and not receiving anticoagulation for other indication. The secondary objective was to analyze the frequencies and predictors of a composite clinical endpoint of death or hospitalization for ischemic stroke.

All adult patients were eligible for study enrolment if they had HF diagnosis documented in their medical history, SR on electrocardiography (ECG), and reduced LVEF < 25% calculated with the biplane Simpson’s method using the apical four chamber (A4C) and apical two chamber (A2C) views during TTE examination. Exclusion criteria were as follows:

- Documented history of AF, atrial high-rate episodes (AHRE) recorded by cardiac implantable electronic devices (CIED), or any other indication for anticoagulation or receiving anticoagulation within 30 days prior to the enrolment.
- Potentially confounding valvular heart disease (any mitral stenosis, moderate or severe aortic stenosis or regurgitation, severe mitral or tricuspid regurgitation).
- Active cancer.
- Inability to provide informed consent.

In patients with acute HF, clinical stabilization was necessary before study enrolment. Patients with systolic blood pressure (BP) < 90 mmHg or > 140 mmHg, diastolic BP > 100 mmHg, or heart rate (HR) < 50 or > 100 beats per minute were not enrolled until BP and HR were normalized.

Data collection
Collected clinical data included age, gender, HF etiology, hypertension, diabetes, chronic kidney disease, history of previous ischemic stroke or transient ischemic attack (TIA), and active cancer. The CHA2DS2-VASc score was calculated for each patient. Height and weight were
measured by a trained observer with the patient wearing in light clothing. Body mass index (BMI) and body surface area (BSA) were calculated. In every participant, TTE followed by TEE were performed on the same day. The participants were followed in prospective cohorts for death and hospitalizations due to ischemic strokes to determine the secondary objective of the study. Data on death and hospitalizations for ischemic strokes were obtained from the official records of the National Health Fund. Written informed consent was obtained from all participants. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki. The study was approved by the appropriate bioethics committee.

**Transthoracic echocardiography**

TTE was performed using the General Electric Vivid E9 device and a sector array M5S (2.5–3.5 MHz) transducer. HR was measured at the time of TTE. Images were acquired to measure LA diameter, LA area, LA volume index (LAVI), and LVEF. LA diameter was measured at the end of the left ventricle systole in the parasternal long axis view. LA area and LAVI were measured in the A4C and A2C views at end systole. Mitral flow velocities with E/A ratios (the ratio of early to late transmitral diastolic velocities) were measured using pulse-wave Doppler. TDI was used to measure e’ values (pulsed-wave TDI-derived mitral annular early diastolic velocity), and E/e’ values were then calculated. All TEE and TTE measurements were performed by a single echocardiography expert.

**Transesophageal echocardiography**

The General Electric Vivid E9 device and a GVT-D (3–8 MHz) transducer were used to perform TEE to allow visualization of left atrial appendage and detection of LAAT. LAAT was diagnosed when a fixed or mobile echogenic mass could be clearly differentiated from the wall of the LA or LA appendage. Patients in whom LAAT was identified had anticoagulation treatment initiated and prescribed at discharge unless contraindicated – the choice among antithrombotic regimens was made at the discretion of the treating physician.

**Left atrial strain analysis**

TDI LA images were obtained with stable ECG tracing in the A4C view (with an interatrial septum and LA lateral wall visible) and the A2C view (attempting to visualize LA inferior and anterior walls). The view angle was obtained by positioning the analysis segment of the LA wall as much as possible along the direction of the ultrasound wave propagation. TDI was performed at a frame rate of over 100 frames per second. TDI echocardiograms including potential sites for strain analysis within the region of interest during at least three cardiac cycles were recorded. TDI recordings were necessary for off-line Q-Analysis as required by the software (General Electric EchoPac workstation, version 112; upgrade BT12). PALS and PACS in six selected regions of interest were analyzed: 1 - within intra-atrial septum at its base and close to the fossa ovalis, 2 - at its superior portion over the fossa ovalis, 3 - within the LA basal lateral wall, 4 - medial lateral wall, 5 - basal inferior wall, and 6 - medial inferior wall. The LA anterior wall was excluded from analysis because of technical difficulties in acquiring accurate images. The P wave was used as the reference point. The negative peak reflecting the extent of myocardial fiber shortening during atrial contraction was evaluated as the lowest value below the baseline and was described as LA contractile strain – PACS. The positive peak strain - PALS, reflecting LA stretching during the LA reservoir phase was recorded as the most positive elevation of the strain curve after the R wave of the QRS complex (Fig. 1). Three measurements from consecutive heart cycles were averaged. Global PALS and global PACS were calculated by averaging respective values observed in all six analyzed LA segments. Recordings for offline strain analyses were made by a single echocardiography expert in all patients at the time of initial TTE. PALS and PACS measurements were performed at the end of the study enrollment by one echocardiography expert who was blinded to patient data.

**Statistical analysis**

Continuous variables are expressed as means ± standard deviation or medians and interquartile ranges, depending on their distribution. Categorical variables are expressed as counts and percentages. The significance of the differences between the study groups was determined using the Student t-test or Mann-Whitney U test for continuous variables and Z² tests for categorical variables. A two-sided p-value ≤0.05 was considered significant. Unconditional univariate logistic regressions were performed to investigate the relationships between each clinical or echocardiographic variable and the risk of LAAT. Next, a multivariate logistic regression model was built using a stepwise forward selection approach. Another logistic regression model was built to identify predictors of a composite clinical endpoint of death or hospitalization for ischemic stroke. Wald chi-square statistic and likelihood ratio tests were used to calculate p-values. The predictive values of selected variables were assessed using receiver-operating characteristic (ROC) analyses. The Youden index was used to determine optimal cut-off values from the ROC curves.

To assess reliability and reproducibility of PALS measurements, 10 sets of TDI TTE recordings of 10 patients from the current study were randomly chosen. PALS analyses were repeated by the echocardiography expert.
who performed the initial measurements and who was experienced in TDI PALS analysis (over 500 patients) and independently by a second echocardiography expert who was only moderately experienced in the PALS analysis using TDI (around 50 patients). The observers were blinded to the patient data. The analysis involved off-line measurements of already acquired data. The observers were allowed to freely choose from several cardiac recorded cycles for each patient. The Bland-Altman method was used to estimate mean differences of intra- and inter-observer variability and the limits of agreement. Intra- and inter-observer reproducibility of PALS measurements was quantified using the intra-class correlation coefficients (ICC), which were generated using one-way ANOVA models. Standard errors of measurement (SEM) were calculated as a root mean square error [13].

Calculations and statistical analyses were performed using Dell Statistica (data analysis software system), version 13. Dell Inc. (2016).

Clinical and echocardiographic data are presented in Table 1. LAAT was detected using TEE in 20 (31.7%) patients. There were no significant differences with regard to the baseline clinical data between patients with and without LAAT. However, the groups differed with regard to some baseline echocardiographic data including LAVI, which was higher in the group with LAAT (68.6 ml/m² (± 9.9) vs. 59.1 ml/m² (± 13.7), p = 0.01), and global PALS and global PACS, which were lower in the group with LAAT (7.2% (± 2.1) vs. 9.7% (± 1.3), p < 0.001 and −3.6% (± 1.1) vs. −4.2% (± 1.2), p = 0.04, respectively). In terms of the follow-up data there were no significant differences. There were more hospitalizations for ischemic strokes in the patients with LAAT but the incidence was low and the difference was not statistically significant (2 patients (10%) in the group with LAAT and 1 patient (2.3%) in the group without LAAT, p = 0.49). A comparison of the baseline characteristics of patients with and without LAAT is displayed in Table 1 and follow-up data is presented in Table 2.

**Results**

**Study population**

From June 2015 to April 2018, a total of 258 patients with SR, HF and LVEF < 25% were screened for eligibility to enter the study. Sixty-three patients who met the selection criteria were included. Of these, 40 (63.5%) had a CIED and 24 (38.1%) underwent 24- or 48-h Holter ECG monitoring during index hospitalization.

**Primary objective - LAAT predictors**

In univariate logistic regression analyses, global PALS was shown to have the highest value in predicting LAAT (OR 0.43 (95% CI – 0.29 - 0.65), p < 0.001, Gini coefficient 0.65). Among all other available clinical and echocardiographic variables, PALS had the lowest odds ratio (inverse relationship) and the highest Gini coefficient (Table 3).
The first step of the multivariate logistic regression model building was the inclusion of global PALS. Following the first step, none of other available variables significantly improved the model. Global PALS remained an independent predictor for LAAT after adjustment for other applicable variables.

![Image](image.png)

The area under the ROC curve (AUC) for global PALS was 0.83 (Fig. 2). The optimal cut-off point from the ROC of global PALS was 7.7%. Given the next unique value of 8.43%, the best cut-off point for this subset could be anywhere between 7.7 and 8.43%; this suggests that the global PALS value of around 8% serves as a good discriminator of LAAT.
Table 2  Follow-up data of patients with and without LAAT confirmed on TEE

|                      | All patients (n = 63) | With LAAT (n = 20, 31.7%) | Without LAAT (n = 43, 68.3%) | p-value |
|----------------------|-----------------------|---------------------------|-------------------------------|---------|
| Death                | 16 (25.4%)            | 5 (25%)                   | 11 (25.6%)                    | 0.96    |
| Hospitalization for ischemic stroke | 3 (4.8%)             | 2 (10%)                   | 1 (2.3%)                      | 0.49    |
| Composite endpoint * | 18 (28.6%)            | 7 (35%)                   | 11 (25.6%)                    | 0.44    |

Values are counts (%). Abbreviations as in Table 1. *Composite clinical endpoint of death or hospitalization for ischemic stroke

Reliability and reproducibility of PALS measurements
The mean difference of intra-observer variability for PALS measurements was −0.1 and the limits of agreement were −0.8 and 0.6. The mean difference of inter-observer variability was −0.6 and the limits of agreement were −3.0 and 1.9. ICC for intra- and inter-observer concordance for PALS measurements were 0.98 (95% CI 0.92–0.99) and 0.77 (95% CI 0.31–0.94), respectively. Intra- and inter-observer SEM were 0.26 (95% CI 0.15–0.37) and 0.92 (95% CI 0.52–1.32), respectively.

Table 3  Ranking of potential predictors for LAAT incidence in the study population based on univariate regression analyses. Sorted by the highest predictive value with Gini coefficients

| Predictor                        | OR      | 95% CI OR | p-value | Gini coefficient |
|----------------------------------|---------|-----------|---------|-----------------|
| Global PALS (%)                  | 0.43    | 0.29      | <0.001  | 0.65            |
| LAVI (ml/m²)                     | 1.06    | 1.01      | 0.01    | 0.44            |
| Global PACS (%)                  | 1.67    | 1.02      | 0.04    | 0.36            |
| Other antiplatelet agent         | 3.27    | 0.86      | 0.08    | 0.18            |
| Ischaemic HF etiology            | 2.14    | 0.71      | 0.18    | 0.18            |
| ACE-I or ARB                     | 2.37    | 0.67      | 0.18    | 0.17            |
| Diabetes                         | 0.56    | 0.17      | 0.34    | 0.12            |
| BSA (m²)                         | 0.26    | 0.01      | 0.4     | 0.11            |
| E/A                              | 1.31    | 0.80      | 0.28    | 0.1             |
| LA diameter (cm)                 | 0.71    | 0.2       | 0.59    | 0.1             |
| E/e`                             | 0.99    | 0.92      | 0.66    | 0.1             |
| CHA2DS2-VASc score               | 1.02    | 0.75      | 0.9     | 0.08            |
| BMI (kg/m2)                      | 0.99    | 0.88      | 0.82    | 0.07            |
| Heart rate (bpm)                 | 0.98    | 0.94      | 0.5     | 0.06            |
| History of stroke or TIA         | 1.72    | 0.35      | 0.51    | 0.06            |
| MRA                              | 0.65    | 0.16      | 0.54    | 0.06            |
| Aspirin                          | 1.3     | 0.30      | 0.73    | 0.04            |
| NYHA class                       |         |           | 0.03    |                 |
| II                               | 1.4     | 0.48      | 4.08    | 0.54            |
| III                              | 0.67    | 0.31      | 1.45    | 0.31            |
| IV                               | 1.07    | 0.48      | 2.38    | 0.88            |
| Beta-blocker                     | 0.68    | 0.10      | 4.4     | 0.68            |
| Statin                           | 0.89    | 0.30      | 2.64    | 0.83            |
| Age (years)                      | 1.01    | 0.96      | 1.06    | 0.67            |
| Hypertension                     | 1.06    | 0.37      | 3.08    | 0.91            |
| LVEF (%)                         | 0.97    | 0.85      | 1.11    | 0.66            |
| Chronic kidney disease           | 1.03    | 0.36      | 3.00    | 0.95            |
| LAA (cm²)                        | 0.99    | 0.92      | 1.07    | 0.85            |

OR Odds ratio, CI Confidence interval. Other abbreviations as in Table 1.
Secondary objective - composite endpoint of death or hospitalization for ischemic stroke

Patients with a confirmed diagnosis of LAAT were discharged and prescribed the following anticoagulants: 2 patients on acenocoumarol, 4 on warfarin, 8 on low molecular weight heparin, 3 on rivaroxaban, 2 on dabigatran, and 1 on apixaban. At a median follow-up of 28.6 months (range 4–40), 18 (28.6%) subjects met the composite clinical endpoint of death or hospitalization due to ischemic stroke (Table 2). The results of univariate regression models for prediction of secondary composite endpoint are presented in Table 4. Neither presence of LAAT nor PALS values were significant predictors of the composite endpoint of death or hospitalization for ischemic stroke. CHA₂DS₂-VASc score, use of ACE-I (angiotensin-converting-enzyme inhibitors) or ARB (angiotensin receptor blockers), and BSA were significant predictors for the composite endpoint of death or hospitalization for ischemic stroke in the multivariate regression model (Table 5).

Discussion

The main finding of this study is that global PALS shows prognostic potential for LAAT identification in patients with HF, very low LVEF, and SR. PALS assessment could be a novel approach to non-invasive stratification of LAAT risk in this group of patients.

Pathophysiological considerations

In healthy people, the lowest pressure in the LA is measured during the conduit phase [9], represented by PALS values. In the case of impaired LA wall extension, PALS is lower and LA pressure may be greater. This pressure is further increased as an effect of LV systolic dysfunction that results in impaired blood inflow into the LA [14]. The increase in LA volume promotes LA wall fibrosis and stiffness, further increasing both the pressure in the LA and the risk of LAAT formation [15]. Low PALS values reflects increased pulmonary capillary wedge pressure [16], and can predict reduced LA appendage emptying velocities [5].

PALS values

LA function assessments could be performed using various methods; it is not clear whether TDI and speckle tracking technique results can be directly compared despite conveying analogous information [17]. Some authors use R-R gating instead of P-P gating, which moves the baseline to the nadir of contractile strain and increases PALS values when compared to P-P gating, as in our study (Fig. 1). As a result, reported absolute values...
of LA longitudinal strain could be as high as 20–30% in patients with mean LVEF < 35% [18]. In one study, in HF patients with LVEF < 35% and SR, global PALS values have been as high as 9.8% ± 4.2 and 16.9% ± 4.0% in patients with and without elevated pulmonary capillary wedge pressure, respectively [16]. The present findings in subjects with SR and LVEF < 25% were lower (average global PALS 9%), probably because of more severe depression in LV function and presumed higher LV filling pressures.

Our reliability and reproducibility analyses of TDI PALS showed very good intra-observer variability and moderately good inter-observer agreement. There is a

Table 4 Results of the univariate regression models for prediction of secondary composite endpoint of death or hospitalization for ischemic stroke. Sorted by Gini coefficients

| Predictor                          | OR    | 95% CI OR | p-value | Gini coefficient |
|-----------------------------------|-------|-----------|---------|-----------------|
| CHA2DS2-VASc score                | 1.51  | 1.07      | 2.12    | 0.02            | 0.38          |
| Age (years)                       | 1.07  | 1.00      | 1.12    | 0.06            | 0.37          |
| BSA (m²)                          | 0.03  | 0.001     | 1.01    | 0.05            | 0.37          |
| Chronic kidney disease            | 3.63  | 1.14      | 11.5    | 0.03            | 0.31          |
| NYHA class                         |       |           |         |                 |               |
| II                                | 0.50  | 0.12      | 2.18    | 0.36            |               |
| III                               | 0.79  | 0.31      | 2.01    | 0.61            |               |
| IV                                | 2.52  | 0.98      | 6.47    | 0.05            |               |
| Heart rate (bpm)                  | 0.95  | 0.91      | 1.01    | 0.08            | 0.28          |
| ACE-I or ARB                      | 0.32  | 0.1       | 1.02    | 0.05            | 0.26          |
| Diabetes                          | 2.75  | 0.88      | 8.56    | 0.08            | 0.23          |
| Ischaemic HF etiology             | 2.29  | 0.73      | 7.16    | 0.16            | 0.2           |
| History of stroke or TIA          | 4.00  | 0.80      | 20.1    | 0.09            | 0.16          |
| LA diameter (cm)                  | 1.16  | 0.32      | 4.15    | 0.82            | 0.12          |
| LAAT                              | 1.57  | 0.50      | 4.93    | 0.44            | 0.1           |
| Aspirin                           | 2.00  | 0.39      | 10.3    | 0.41            | 0.09          |
| LAVI (ml/ m²)                     | 1.01  | 0.97      | 1.05    | 0.74            | 0.09          |
| LVEF (%)                           | 0.96  | 0.84      | 1.09    | 0.50            | 0.09          |
| MRA                               | 0.54  | 0.13      | 2.19    | 0.39            | 0.09          |
| BMI (kg/m2)                       | 1.00  | 0.89      | 1.13    | 0.94            | 0.08          |
| E/A                               | 1.01  | 0.94      | 1.07    | 0.85            | 0.07          |
| Global PACS (%)                   | 1.13  | 0.71      | 1.79    | 0.62            | 0.07          |
| E/A                               | 1.11  | 0.68      | 1.84    | 0.67            | 0.06          |
| Global PALS (%)                   | 0.97  | 0.74      | 1.29    | 0.84            | 0.05          |
| Beta-blocker                      | 0.57  | 0.09      | 3.74    | 0.56            | 0.04          |
| Digoxin                           | 2.59  | 0.15      | 43.7    | 0.51            | 0.03          |
| LA area (cm²)                     | 0.99  | 0.92      | 1.07    | 0.83            | 0.03          |
| Hypertension                      | 1.09  | 0.37      | 3.28    | 0.87            | 0.02          |
| Female sex                        | 1.27  | 0.11      | 14.9    | 0.85            | 0.01          |
| Other antiplatelet agent          | 0.93  | 0.22      | 3.97    | 0.92            | 0.01          |
| Statin                            | 0.95  | 0.31      | 2.93    | 0.93            | 0.01          |

Abbreviations as in Table 1 and Table 3

Table 5 Results of the multivariable regression model for prediction of secondary composite endpoint of death or hospitalization for ischemic stroke

| Predictor                          | OR    | 95% CI OR | p-value | Gini coefficient |
|-----------------------------------|-------|-----------|---------|-----------------|
| CHA2DS2-VASc score                | 1.7   | 1.2       | 2.5     | 0.006           |
| ACE-I or ARB                      | 0.2   | 0.05      | 0.8     | 0.02            |
| BSA (m²)                          | 0.02  | 0.0003    | 0.9     | 0.046           |

Abbreviations as in Table 1 and Table 3
significant learning curve associated with LV strain analysis by speckle tracking echocardiography [19]. Our analysis also suggests that although global PALS assessment by TDI is reproducible, an echocardiographer should have some experience in this method to produce more reliable measurements.

LAAT prediction
LAAT is rarely present in patients with SR and normal LVEF [20, 21]. Nevertheless, in specific groups of patients, LAAT is more frequent. This includes patients with mitral stenosis, AF, atrial flutter, or LV systolic dysfunction [21–23]. A study in patients with AF showed that global PALS together with LA volume and increased E/e’ ratio was useful for predicting LAAT, while global PALS demonstrated the highest diagnostic accuracy [5]. The risk is greater in patients with LV systolic dysfunction regardless of heart rhythm [24–26]. Another study reported that LA deformation parameters measured by 2D speckle tracking predicted the presence of LAAT in ischemic stroke patients who were in SR [20]. Nevertheless, those patients had normal LVEF and only nine subjects with LAAT were identified. In the present study, we confirmed the prognostic value of PALS in predicting LAAT in patients with LV systolic dysfunction and SR. In our study, only two other echocardiographic variables (LAVI and global PACS) were significant predictors of LAAT in the univariate analysis; however, they convey less predictive information than does PALS and became obsolete in multivariate analysis once global PALS was included in the model.

In AF patients, a global PALS cut-off values less than 8.1% had good sensitivity and specificity to predict LAAT [5]. We found a similar value as an optimal cut-off point in patients with SR. This most likely suggests that global PALS of around 8% may be a strong independent predictor of LAAT, whether in SR or AF. In our study population, global PALS < 8% increased the risk of LAAT over 30-fold.

Possible clinical implications
There is currently no recommendation for active screening for LAAT in the general population of HF patients. In our cohort of patients with very low LVEF (but without a diagnosis of AF) LAAT was present in 31.7%. This translates into a potentially large population of patients who may be candidates for antithrombotic treatment. Currently, the decision to initiate anticoagulation needs to be made after confirmation of LAAT using established imaging modalities. Nevertheless, PALS assessment may identify patients who might be candidates for such additional testing.

Routine use of anticoagulation in HF patients is currently not recommended [4, 27]; however, individualized decisions should be made, accounting for individual thromboembolic risks. The benefits of antithrombotic treatment in patients with severe LV systolic dysfunction and LAAT are rarely documented in clinical trials. Following current recommendations [4], we initiated anticoagulation if LAAT was confirmed using TEE. Therefore, we did not directly address the question of benefits of such therapy. The limited life expectancy of these severely ill patients with very low LVEF is another factor to be considered when translating LAAT presence into potential clinical implications.

Some clinical variables have been reported to have prognostic value for unfavorable clinical outcomes in HF patients in SR. These include hypertension, lower ejection fraction [1], prior stroke/TIA, and diabetes [3]. The assessment of LA reservoir strain provides additional risk stratification for stroke in AF patients [28], offering incremental value over the CHA2DS2-VASc score [29]. CHA2DS2-VASc is a well-established risk score for thromboembolic complications and stroke in AF patients. Nevertheless, the usefulness of the CHA2DS2-VASc score in patients with SR is limited and its predictive accuracy for thromboembolic events or death appears only modest [30]. We found it to be the strongest predictor of our secondary composite endpoint of death or hospitalization for ischemic stroke. The positive impact of the use of ACE-I or ARB on clinical outcomes is not surprising given well-established benefits of these drugs in HF patients with reduced LVEF [27]. The borderline significance of BSA in our secondary endpoint analysis may reflect the so-called obesity paradox. It is well established that obesity is associated with lower mortality in HF patients, as is seen in other chronic illnesses [27]. In our study, neither PALS value nor LAAT had prognostic value in terms of the composite endpoint of all-cause mortality or hospitalization due to ischemic stroke. Nevertheless, LAAT is a potentially modifiable condition that is effectively treated with anticoagulants. In our study, the patients with LAAT had anticoagulation treatment initiated at the time of the diagnosis and stroke rates in this group could have been reduced, possibly explaining why we did not find a significant association between LAAT or PALS and our chosen clinical outcomes.

Limitations
Women were underrepresented in our study. The patients were selected based on “real-life” clinical practice criteria – if they had no history of AF or AHRE nor other established indications for anticoagulation, they were considered eligible for the study. The study protocol did not require any intentional screening for AF and it was possible that some of the included patients
experienced silent paroxysms of AF. Nevertheless, many of included patients had CIEDs and underwent regular cardiologic monitoring to allow detection of possible indications for anticoagulation. Furthermore, some of the included patients underwent Holter ECG monitoring during the index hospitalization as a part of routine clinical practice. If any of these modalities confirmed AF or AHRE, the patients were not included in the study. The actual ischemic stroke rates were low; however, this rate could be biased by the fact that patients in whom LAAT was identified were treated with anticoagulation agents. No data were collected regarding the adherence to the anticoagulant therapy nor information if the medications recommended at discharge were later changed or withdrawn. The lack of this data may affect the secondary endpoint interpretation. Further research is needed to determine whether the initiation of anticoagulation or additional screening supported by PALS measurements improves clinical outcomes in such patients.

Conclusions

PALS has prognostic potential in LAAT identification in patients with HF, LVEF < 25%, and SR and without established indication for antithrombotic treatment. Global PALS values < 8% identify a group of patients with considerably higher risk of LAAT. LAAT was a relatively common finding in this group of HF patients.

Abbreviations

A2C: Apical two chamber; A4C: Apical four chamber; ACE-I: Angiotensin-converting-enzyme inhibitors; AF: Atrial fibrillation; AHRE: Atrial high-rate episodes; ARB: Angiotensin receptor blockers; AUC: Area under the ROC curve; BMI: Body mass index; BP: Blood pressure; BSA: Body surface area; CI: Confidence intervals; CIED: Cardiac implantable electronic devices; E/A: The ratio of early to late transmural diastolic velocities; e': Pulsed-wave TDI-derived mitral annular early diastolic velocity; ECG: Electrocardiography; HF: Heart failure; HR: Heart rate; ICC: Intraclass correlation coefficient; LA: Left atrium; LAA: Left atrium area; LAAT: Left atrial appendage thrombus; LAVI: Left atrial volume index; LV: Left ventricle; LVEF: Left ventricular ejection fraction; MRA: Mineralocorticoid receptor antagonist; NYHA: New York Heart Association; PACE: Peak atrial contraction strain; PALS: Peak atrial longitudinal strain; ROC: Receiver-operating characteristic; SEM: Standard error of measurement; SR: Sinus rhythm; TDI: Tissue Doppler imaging; TEE: Transesophageal echocardiography; TTE: Transthoracic echocardiography

Acknowledgements

Not applicable.

Authors’ contributions

JK - Concept/design, data collection, data interpretation, approval of article. AJS - Data interpretation, critical revision of article, approval of article. LZ - Drafting article, statistics, data collection, data interpretation, approval of article. LP - Data collection, data interpretation critical revision of article, approval of article. DK - Critical revision of article, approval of article. MS - Critical revision of article, approval of article.

Funding

The project is supported under the program of the Minister of Science and Higher Education under the name “Regional Initiative of Excellence” in 2019–2022 project number: 024/RID/2018/19, financing amount: 11.999.000,00 PLN.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The study was approved by the Bioethics Committee at the Swietokrzyska Chamber of Physicians. Signed informed consent was obtained from all participants.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1Swietokrzyskie Cardiology Centre, Kielce, Poland. 2The Jan Kochanowski University, ul. Stefana Zeromskiego 5, 25-001 Kielce, Poland.

Received: 20 May 2019 Accepted: 4 February 2020

Published online: 15 February 2020

References

1. Freudenberger RS, Hellaampi AS, Halperin JL, Poole J, Anderson J, Johnson G, et al. Risk of thromboembolism in heart failure: an analysis from the sudden cardiac death in heart failure trial (SCD-HeFT). Circulation. 2007;115:2637–41.
2. Di Tullio MR, Qian M, Thompson JL, Labovitz AJ, Mann DL, Sacco RL, et al. Left ventricular ejection fraction and risk of stroke and cardiac events in heart failure: data from the warfarin versus aspirin in reduced ejection fraction trial. Stroke. 2016;47:2031–7.
3. Pullicino PM, McClure LA, Howard VJ, Wadley VG, Safford MM, Meschia JF, et al. Identifying a high stroke risk subgroup in individuals with heart failure. J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc. 2013;22:2620-6.
4. Lip GYH, Ponikowski P, Andreotti F, Anker SD, Filippatos G, Homma S, et al. Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC heart failure association and the ESC working group on thrombosis. Thromb Haemost. 2012;108:1009–22.
5. Cameli M, Lunghetti S, Mandalii GE, Righini FM, Lisi M, Curci V, et al. Left atrial strain predicts pro-thrombotic state in patients with non-Valvular atrial fibrillation. J Atr Fibrillation. 2017;10:1641.
6. Vannia-Pinton R, Moreno CA, Baxter CM, Lee KS, Tsang TSM, Appleton CP. Two-dimensional speckle-tracking echocardiography of the left atrium: feasibility and regional contraction and relaxation differences in normal subjects. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr. 2009;22:299-305.
7. Miyoshi A, Nakamura Y, Kazanji Y, To H. The feasibility of substituting left atrial wall strain for flow velocity of left atrial appendage. Acta Cardiol. 2018;73:125–30.
8. Kuztawski J, Janion-Sadowska A, Sadowski M. Left atrial appendage function assessment and thrombus identification. Int J Cardiol Heart Vasc. 2017;14:33–40.
9. Blume GG, Mcleod CJ, Barnes ME, Seward JB, Pellikka PA, Bastiansen PM, et al. Left atrial function: physiology, assessment, and clinical implications. Eur J Echocardiogr. 2011;12:421–30.
10. Malagoli A, Rossi L, Bursi F, Zanni A, Sticozzi C, Piepoli MF, et al. Left atrial function predicts cardiovascular events in patients with chronic heart failure with reduced ejection fraction. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr. 2019;32:248–56.
11. Ahmed MK, Soliman MA, Reda AA, Abd El-Ghani RS. Assessment of left atrial deformation properties by speckle tracking in patients with systolic heart failure. Egypt Heart J. 2015;67:199–208.
12. Kuztawski J, Janion-Sadowska A, Gackowski A, Janion M, Zandecki L, Chrapek M, et al. Left atrial longitudinal strain in dilated cardiomyopathy patients: is there a discrimination threshold for atrial fibrillation? Int J Card Imaging. 2019;35:319–25.
13. Popovic ZB, Thomas JD. Assessing observer variability: a user’s guide. Cardiovasc Diagn Ther. 2017;7:317–24.
14. Pathan F, D’Elia N, Nolan MT, Manwick TH, Negishi K. Normal Ranges of Left Atrial Strain by Speckle-Tracking Echocardiography: A Systematic Review and Meta-Analysis. J Am Soc Echocardiogr. 2017;30:59–70.e8.
15. Delgado V, Di Biase L, Leung M, Romero J, Tops LF, Casadei B, et al. Structure and function of the left atrium and left atrial appendage. AF and stroke implications. J Am Coll Cardiol. 2017;70:3157–72.
16. Cameli M, Lisi M, Mondillo S, Padeletti M, Ballo P, Tsiourpas C, et al. Left atrial longitudinal strain by speckle tracking echocardiography correlates well with left ventricular filling pressures in patients with heart failure. Cardiovasc Ultrasound. 2010;8:14.
17. Wang Y, Li Z, Fei H, Yu Y, Ren S, Lin Q, et al. Left atrial strain reproducibility using vendor-dependent and vendor-independent software. Cardiovasc Ultrasound. 2019;17:9.
18. D’Andrea A, Caso P, Romano S, Scarafile R, Riegler L, Salerno G, et al. Different effects of cardiac resynchronization therapy on left atrial function in patients with either idiopathic or ischaemic dilated cardiomyopathy: a two-dimensional speckle strain study. Eur Heart J. 2007;28:2739–48.
19. Chan J, Shino K, Obonyo NG, Hanna J, Chambetlait R, Small A, et al. Left ventricular global strain analysis by two-dimensional speckle-tracking echocardiography: the learning curve. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr. 2017;30:1081–90.
20. Karabay CY, Zehir R, Güler A, Oduncu V, Kalayci A, Aung SM, et al. Left atrial deformation parameters predict left atrial appendage function and Thrombus in patients in sinus rhythm with suspected Cardioembolic stroke: a speckle tracking and transesophageal echocardiography study. Echocardiography. 2013;30:572–81.
21. Yoran A, Khandheria Bijoy K, gentile Federico, Seward James B. clinical and echocardiographic characteristics of patients with left atrial Thrombus and sinus rhythm. Circulation. 2002;105:27–31.
22. Ellis K, Ziada KM, Vivekananthan D, Latif AA, Shaarouli M, Martin D, et al. Transthoracic echocardiographic predictors of left atrial appendage Thrombus. Am J Cardiol. 2006;97:421–5.
23. Gunawardene MA, Dickow J, Schaeffer BN, Akbulak RÖ, Lemoine MD, Nührich JM, et al. Risk stratification of patients with left atrial appendage thrombus prior to catheter ablation of atrial fibrillation: an approach towards an individualized use of transesophageal echocardiography. J Cardiovasc Electrophysiol. 2017;28:1127–36.
24. Divani AA, Vazquez G, Asadollahi M, Qureshi AJ, Pullicino P. Nationwide frequency and association of heart failure on stroke outcomes in the United States. J Card Fail. 2009;15:1–6.
25. Vemmos K, Ntafos G, Savvai P, Vemmou AM, Koroboki E, Manios E, et al. Stroke aetiology and predictors of outcome in patients with heart failure and acute stroke: a 10-year follow-up study. Eur J Heart Fail. 2012;14:211–8.
26. Kasanos AH, Parissis J, Frogoudaki A, Vrettou A-R, Konoumidis I, Paraskavaidis I, et al. Heart failure and the risk of ischemic stroke recurrence: a systematic review and meta-analysis. J Neurol Sci. 2016;362:182–7.
27. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). J Am Coll Cardiol. 2016;67:2129–220.
28. Leung M, van Rosendaal PJ, Abou R, Ajmone Marsan N, Leung DY, Delgado V, et al. Left atrial function to identify patients with atrial fibrillation at high risk of stroke: new insights from a large registry. Eur Heart J. 2018;39:1416–25.
29. Kupczyńska K, Michalski BW, Miskowiec D, Kasprzak JD, Szymczyk E, Wejner Młk P, et al. Incremental value of left atrial mechanical dispersion over CHA2 DS2-VASC score in predicting risk of thrombus formation. Echocardiogr Mt Kisco N. 2018;35:651–60.
30. Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lipton G. Assessment of the CHA2DS2-VASC score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation. JAMA. 2015;314:1030–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.